https://assets.capyfin.com/instruments/678fdc13234e27009c5d5c34.png avatar
Cardlytics
🇺🇸 NASDAQ:CDLX
View Company
OverviewEarningsDividends
•
Dec 31, 2020

Cardlytics Q4 2020 Earnings Report

Cardlytics' Q4 2020 financial results showed a slight decrease in revenue compared to the previous year, but exceeded prior guidance. The company reported a net loss and a decrease in billings, but saw an increase in average FI MAUs.

Key Takeaways

Cardlytics announced its Q4 2020 financial results, with total revenue decreasing by 3.2% to $67.1 million compared to Q4 2019. The company reported a net loss attributable to common stockholders of $(6.8) million, or $(0.24) per diluted share, and a non-GAAP net loss of $(1.5) million, or $(0.05) per diluted share. Average FI MAUs increased by 22.6% to 163.6 million, while ARPU decreased by 21.2% to $0.41.

Total revenue decreased by 3.2% to $67.1 million compared to Q4 2019.

Net loss attributable to common stockholders was $(6.8) million, or $(0.24) per diluted share.

Non-GAAP net loss was $(1.5) million, or $(0.05) per diluted share.

Average FI MAUs increased by 22.6% to 163.6 million, while ARPU decreased by 21.2% to $0.41.

Total Revenue
$67.1M
Previous year: $69.3M
-3.2%
EPS
-$0.05
Previous year: $0.18
-127.8%
Monthly Active Users
163.6M
Previous year: 133.4M
+22.6%
Average Revenue per User
$0.41
Previous year: $0.52
-21.2%
Gross Profit
$24.8M
Cash and Equivalents
$293M
Previous year: $104M
+180.7%
Free Cash Flow
$2.9M
Total Assets
$423M

Cardlytics

Cardlytics

Forward Guidance

Cardlytics anticipates billings, revenue, and adjusted contribution to be in the following ranges (in millions):

Positive Outlook

  • Q1 2021 Billings: $67.0 - $75.0 million
  • Q1 2021 Revenue: $47.0 - $53.0 million
  • Q1 2021 Adjusted contribution: $20.0 - $24.0 million
  • FY 2021 Billings: $360.0 - $400.0 million
  • FY 2021 Revenue: $250.0 - $275.0 million

Company Overview

Full financial data and analysis

View Cardlytics